At jMedtech, our commitment to patient well-being is at the heart of everything we do. We understand the critical importance of preventing blood clot formation in medical devices, and that's why we've dedicated significant resources to developing innovative antithrombogenic coatings and heparin coated solutions.
Our Hygea® heparin coated technology represents a significant advancement in the field of biocompatible medical devices. This specialized antithrombogenic coating is designed to enhance device performance and, most importantly, improve patient safety.
The Hygea® coating is chemically bonded to the surface of medical devices, grafting modified heparin onto the surface. This process effectively inhibits the formation of thrombus, ensuring long-term performance. Unlike some coatings that degrade over time, Hygea® maintains its integrity and function even with extended use.
Heparin, a naturally occurring anticoagulant, is the key to Hygea®'s effectiveness. By immobilizing heparin on the device surface, we create a barrier that prevents blood from clotting. This is achieved through effectively reducing protein and platelet adhesion, thus minimizing the risk of thrombus formation.
jMedtech has incorporated its antithrombogenic coatings into 11 different products, showcasing a broad foundation of uses and extensive experience. The coated products have demonstrated a significant anti-coagulative effect.
Our Hygea® coating is trusted across a diverse spectrum of medical devices, reflecting its proven versatility and performance. Applications range from stent grafts, metal implants, and introducer sheaths to central venous catheters (CVC), heart valves, and vascular grafts. It is equally effective in specialized devices such as neurological guidewires and catheters, haemodialysis catheters, embolic protection systems, vena cava filters, and peripherally inserted central catheters (PICC). This wide adoption underscores the adaptability of our advanced antithrombogenic coating technology, engineered to reduce clot formation, improve hemocompatibility, and enhance long-term device safety. Whether for short-term interventions or long-term implants, Hygea® delivers consistent, validated performance in critical clinical applications.
Hygea® boasts excellent biocompatibility and is applied at the nanometer level. This ensures that the coating interacts seamlessly with the body, minimizing adverse reactions.
In conclusion, as jMedtech, we are proud to be at the forefront of antithrombogenic coating technology. Our Hygea® heparin coated devices are designed to provide superior protection against blood clot formation, ultimately enhancing patient safety and improving outcomes. We remain committed to innovation in this critical area, continuously seeking new ways to improve the biocompatibility and performance of our medical devices.
